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Abstract
Background: To evaluate the association between single nucleotide polymorphisms (SNPs) at the 194 and 399
codons of XRCC1, and the risk of severe acute skin and oral mucosa reactions in nasopharyngeal carcinoma patients
in China.
Methods: 114 patients with nasopharyngeal carcinoma were sequentially recruited in this study. Heparinized
peripheral blood samples were taken for SNPs analysis before the start of radiation treatment. SNPs in XRCC1
(194Arg/Trp and 399Arg/Gln) gene were analyzed by polymerase chain reaction-restriction fragment length
polymorphism (PCR-RFLP). Dermatitis at upper neck and oral mucositis were clinically recorded according to the
Common Terminology Criteria for Adverse Events v.3.0.
Results: The variant allele frequencies were 0.289 for XRCC1 194Trp and 0.263 for XRCC1 399Gln. Of the 114 patients,
24 experienced grade 3 acute dermatitis and 48 had grade 3 acute mucositis. The XRCC1 399Arg/Gln was
significantly associated with the development of grade 3 dermatitis (Odds Ratio, 2.65; 95% CI, 1.04–6.73; p = 0.037,
χ2 = 4.357). In addition, it was also associated with higher incidence of grade 3 mucositis with a borderline
statistical significance (Odds Ratio, 2.11; 95% CI, 0.951–4.66; p = 0.065, χ2 = 3.411). The relationship between XRCC1
194Arg/Trp and acute dermatitis, and mucositis was not found.
Conclusions: Our investigation shows, for the first time, that patients with the XRCC1 399Arg/Gln genotype were
more likely to experience severe acute dermatitis and oral mucositis. With further validation, the information can be
used to determine personalized radiotherapy strategy.
Keywords: Single nucleotide polymorphisms (SNPs), X-ray cross-complementing group 1 (XRCC1), Nasopharyngeal
carcinoma (NPC), Radiotherapy, Acute skin reactions, Acute mucosa reactions
Background
Nasopharyngeal carcinoma (NPC) is prevalent in certain
parts of the world: Southern China, North Africa, and
parts of the Mediterranean basin [1]. Radiation therapy
(RT) alone or in combination with chemotherapy are the
standard treatments of NPC and the overall 5 year
survival rate is between 59% and 85% [2,3]. However,
radiation-induced toxicity limits the use of higher doses
to further improve efficacy. Balancing between treatment
efficiency and toxicity of RT is always a dilemma to
radiation oncologist.
The severity of RT-induced complication is associated
with many factors: radiation dose, combined with che-
motherapy, types of tissues, and microenvironment of
involved tissues. However, similar patients who received
similar or identical treatment protocols had substantially
different degree of clinical side effects. Therefore, genetic
component may contribute to the clinical radiosensiti-
vity [4-6].
As RT exerts its cytotoxic effects through damage
to cells, proteins, and DNA, individual variations in the
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repair of DNA damage may modify the response of nor-
mal tissues [7]. Polymorphisms of X-ray repair cross-
complementing group 1 (XRCC1), a base excision repair
(BER) gene, was shown to affect DNA repair activity, cell
cycle progression, and sensitivity to bleomycin, a radia-
tion-mimicking agent that induces double-strand breaks
in DNA [8,9].
In NPC patients, the 399Gln variant XRCC1 gene was
reported to be associated with lower grade fibrosis after
radiation therapy in a small number of patients [10].
Using immunohistochemical techniques, the lack of
ERCC1 staining was associated with increased radiosen-
sitivity [11]. On the other hand, high staining intensity
of the ERCC1 protein was associated with poor loco-
regional control of the carcinoma [12]. Clearly, these
studies do not provide consistent or adequate informa-
tion on radiosensitivity that can be used to modify thera-
peutic protocols. Therefore, we have conducted our study
using an enhanced experimental design.
Numerous studies have examined the association of
DNA repair SNPs with acute and late RT normal tissue
effects. XRCC1 gene was the one frequently investigated
in DNA repair gene family. The results of association
between XRCC1 SNP and radio- response were in con-
sistent [13]. From this point, we have conducted this
genetic polymorphism study on relevant XRCC1 alleles.
In addition, we associated the polymorphisms with acute
mucositis and dermatitis which are common side-effects
from radiation therapy among NPC patients.
Methods
Patient characteristics and clinical parameters
Between Nov, 2009 and Dec, 2010, 114 patients with his-
tologically confirmed NPC were recruited to this study
in the Cancer Hospital, Shantou University Medical Col-
lege, China. The study was approved by the local ethics
committee and informed consent was obtained from all
patients enrolled. Patients without systemic metastasis
and receiving definite RT alone or combined with che-
motherapy were eligible to the study. In the period of
study, totally 380 consecutive patients were eligible to
the study. Among them, 114 patients consented to the
study.
Evaluation by physical examination, nasopharyngeal
endoscope, Magnetic Resonance Imaging of nasopharynx
and neck, chest X-ray, and abdominal ultrasonography
were routinely performed for tumor staging. Skeletal scan-
ning by single photon emission computed tomography
was selected to patients with stage N2-3 disease. The over-
all stage distribution was 11.4% (13/114) for stages II;
40.4% (46/114) for stage III; and 48.2% (55/114) for stages
IV by AJCC staging system V7 [14].
The enrolled patients consisted of 36 females and
78 males with age of 19–76 (mean 49.6, SD 11.9). One
hundred and twelve patients had World Health Orga-
nization (WHO) type II or III tumor. Two had WHO
type I tumor. Ninety-five patients received combined
chemo-radiotherapy with cisplatin-based single or doub-
let scheme, and 19 received radiotherapy alone. The
combination strategies were selected based on tumor
stage and patient’s performance status. Three-dimensio-
nal conformal radiation therapy (3D-CRT) or intensity
modulated radiotherapy (IMRT) were used for radio-
therapy. In using 3D-CRT, the prescription doses were
70 Gray (Gy) in 35 fractions (Fs) (70Gy/35Fs) to primary
tumor, 68Gy/34Fs to involved cervical drainage regions,
and 50Gy/25Fs to uninvolved cervical drainage regions.
In using IMRT, the prescription doses were 70Gy/32-
33Fs to primary tumor, 66-68Gy/32-33Fs to cervical no-
dular lesions, 60Gy/32-33Fs to involved cervical drainage
regions, and 54Gy/32-33Fs to uninvolved cervical drain-
age regions. All radiotherapies were delivered once daily,
5 days weekly.
Study endpoints
Radiation-induced acute dermatitis and mucositis were
the endpoints of this study. The upper neck was selected
as evaluation area, considering all patients received
irradiation to their upper neck. In addition, the foldless
skin of upper neck might eliminate the unplanned extra
dose to the folded region caused by build-up effect of
beams. The acute dermatitis and mucositis were scored
by the Common Terminology Criteria (CTC) for adverse
events v3.0 scale [15]. The highest grade of toxicity was
chosen as the reference value. It was evaluated and
documented weekly from the beginning to the end of
radiotherapy. All scores of dermatitis and mucositis were
confirmed by the same senior consultant physician as to
eliminate the observer bias.
Calculation of radiation doses to interesting regions
The irradiation dose to the observed skin areas was
generated by the method reported in the literature previ-
ously [6]. Briefly, a rim of 5mm beneath the external
contour of upper neck was created and used as a surro-
gate for the epidermis and dermis, which extended to
the edge of mandible cranially and level C6 vertebra
caudally. The average dose to the rim was calculated to
represent the doses received by the observed skin. The
average dose to oral cavity was taken as the reference
dose received by oral mucosa. In axis CT image, the
region between the outer edge of gum and anterior edge
of tonsillar fossa was contoured as oral cavity, which
extended from the floor of the mouth to the hard palate
and soft palate. All contouring and calculations were
performed using the Pinnacle3W (version 8.0m) treatment
planning system (Phillips, Madison, WI, US).
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Genotyping analysis
A heparinized peripheral blood sample of 1ml was taken
before the start of treatments. Genomic DNA was
extracted from whole blood samples using the TIANamp
Extraction Kit (Tiangen, Beijing, China). The polymor-
phic sites in XRCC1 (194Arg/Trp and 399Arg/Gln) were
analyzed by Polymerase Chain Reaction–Restriction Frag-
ment Length Polymorphism (PCR- RFLP) using Planti-
num Taq DNA polymerase (Invitrogen, Shanghai, China)
for PCR and PvuII and MspI (NEB, Beijing, China) for
digestion as reported in literature [8]. In addition, 10% of
randomly selected samples were sequenced to verify geno-
typing results and 100% concordance was found.
Statistical analysis
All analyses were performed using SPSS software, ver-
sion 13.0 (SPSS, Chicago, IL). Each polymorphism was
tested for deviation from Hardy-Weinberg equilibrium
by comparing the observed and expected genotype
frequencies using the chi-square test with 1° of freedom.
A p value of 0.05 or less (in a two-sided test) was consid-
ered statistically significant. Patients were subdivided
according to their CTC score of dermatitis and muc-
ositis. Patients who experienced episodes of grade 3 or
higher toxicity were defined as radiation sensitive (Grade
3) and those with milder toxicity were defined as ra-
diation insensitive (Grade 1–2). The Grade 3 vs. Grade
1–2 frequencies were examined by calculating the odds
ratios (OR), with 95% confidence interval (95% CI) using
the chi-square test, with that of wild-type alleles as the
reference.
The effect of age, gender, smoking, alcohol drinking,
body mass index, tumor stage, radiotherapy technique,
and radiation dose to observed tissue volumes on clini-
cal radiosensitivity was also evaluated using the student's
t test or the chi-square test.
Results
Over all acute reactions of skin and oral mucosa
Acute radiation-induced dermatitis in the upper neck
and mucositis in the oral cavity were the clinical end-
points of this study. Of the 114 patients, 31 (27.2%)
experienced grade 1, 59 (51.8%) grade 2, and 24 (21.1%)
grade 3 skin toxicity. In addition, 24 (21.1%) had grade
1, 42 (36.8%) grade 2, and 48 (42.1%) grade 3 acute oral
mucositis. There was no grade 4 or grade 5 toxicities of
skin or mucosa observed during the treatment.
Distribution of allele frequencies for XRCC1 (194Arg/Trp
and 399Arg/Gln)
Overall, the variant allele frequencies were 0.289 for
XRCC1 194Trp and 0.263 for XRCC1 399Gln. All the
genotype distributions were in Hardy-Weinberg equilib-
rium (p>0.05 at the chi-square for each allele).
Because of low frequency (<10%) of the genotypes of
XRCC1 (194 Trp/Trp) and XRCC1 (399 Gln/Gln), we
did not calculate the association between each of these
genotypes and acute reactions.
Polymorphisms in XRCC1 gene and skin reaction
Table 1 shows the distribution of alleles Arg/Trp, Arg/
Trp or Trp/Trp for XRCC1 at codon 194. Compared with
XRCC1 194 Arg/Arg (wild-type), the XRCC1 194Arg/Trp
was associated with lower incidence of grade 3 acute skin
toxicity. The risk odds rate was 0.70 or less. However, the
difference was not statistically significant.
The XRCC1 399Arg/Gln was associated with high risk
of grade 3 skin toxicity, OR = 2.65 (95% CI: 1.04–6.73),
compared to the wild-type. It was statistically significant
as tested by the chi-square test (p = 0.037, χ2 = 4.357).
Polymorphisms in XRCC1 gene and reaction of oral mucosa
In Table 2, the results show that the XRCC1 194Arg/Trp
was associated with lower incidence of grade 3 acute
oral mucositis, compared with the Arg/Arg allele. But it
was not statistically significant.
Table 1 Association of polymorphisms in XRCC1 and the
risk of acute dermatitis
Dermatitis
Genotype Grade 1–2 Grade 3 OR (95% CI) p value
XRCC1 (194Arg/Trp)
Arg/Arg (wild-type) 41 14 1.00 (ref)
Arg/Trp 42 10 0.697 (0.278–1.75) 0.440
Trp/Trp 7 0 NC NC
XRCC1 (399Arg/Gln)
Arg/Arg (wild-type) 53 10 1.00 (ref)
Arg/Gln 28 14 2.65 (1.04–6.73) 0.037
Gln/Gln 9 0 NC NC
Abbreviations: ref = reference; NC = not calculated; OR = Odds ratio; 95%CI = 95%
confidence interval.
Table 2 Association of polymorphisms in XRCC1 and the
risk of acute oral mucositis
Mucositis
Genotype Grade 1–2 Grade 3 OR (95% CI) p value
XRCC1 (194Arg/Trp)
Arg/Arg (wild-type) 31 24 1.00 (ref)
Arg/Trp 33 19 0.744 (0.342–1.62) 0.454
Trp/Trp 2 5 NC NC
XRCC1 (399Arg/Gln)
Arg/Arg (wild-type) 40 23 1.00 (ref)
Arg/Gln 19 23 2.11 (0.951–4.66) 0.065
Gln/Gln 7 2 NC NC
Abbreviations: ref = reference; NC = not calculated; OR = Odds ratio;
CI = confidence interval.
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Compared to the wild type, XRCC1 399Arg/Gln was
associated with higher incidence of grade 3 oral mucosa
toxicity, OR = 2.11 (95% CI: 0.951-4.66). The difference
was borderline statistically significant, as tested by
chi-square (p = 0.065, χ2 = 3.411).
Clinical factors and acute reactions
The relationship between acute reaction of skin and mu-
cus, and factors of age, gender, smoking, alcohol drin-
king, body mass index, tumor stage, and chemotherapy,
radiotherapy technology, and radiation dose to observed
tissue volumes were also evaluated with univariate
analyses. No linkage between the observed endpoint and
the above mentioned factors were found (details are
shown in Table 3).
Discussion
To our knowledge, this study is the first investigation of
genetic association between variants in XRCC1 (194Arg/
Trp and 399Arg/Gln) and the risk of acute skin reaction
and mucosa toxicity in NPC patients treated with RT.
Table 3 Association of clinical factors and the risk of acute skin and oral mucosa reactions
Dermatitis Mucositis
Grade 1–2 Grade 3 p value Grade 1–2 Grade 3 p value
Age (year)
Mean±SD 49.3±12.3 50.8±10.2 0.587 48.2±12.5 51.5±10.7 0.144
Gender
Male 61 17 0.775 48 30 0.246
Female 29 7 18 18
Drinking
Yes 8 1 0.737 4 5 0.617
No 82 23 62 43
Smoking
Yes 49 12 0.698 36 25 0.795
No 41 12 30 23
Body mass index
≤25 73 20 1.00 55 38 0.571
>25 17 4 11 10
T-staging
T1 8 1 0.418 5 4 0.474
T2 27 5 22 10
T3 29 7 18 18
T4 26 11 21 16
N-staging
N0 10 0 0.240 8 2 0.219
N1 19 5 12 12
N2 46 12 36 22
N3 15 7 10 12
Chemotherapy
Yes 77 21 1.00 55 43 0.343
No 13 3 11 5
Radiotherapy technique
3D-CRT 40 8 0.327 29 19 0.642
IMRT 50 16 37 29
Irradiation Dose (Gy)
Mean±SD 42.37±5.09 43.16±4.43 0.493 29.48±10.16 30.92±10.38 0.460
Abbreviations: IMRT = intensity-modulated radiotherapy; 3D-CRT = three-dimensional conformal radiation therapy, SD = Standard deviation. Gy=Gray.
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The other one studies involved tissue fibrosis and geno-
type analysis with much smaller sample size [10].
In our study, the frequencies of the variant alleles were
0.289 (XRCC1-194Arg/Trp) and 0.263 (XRCC1-399Arg/
Gln), which were consistent with the previous literature
data in Chinese subjects [16,17]. However, the allele fre-
quencies were different from those previously reported in
Caucasian populations (the variant alleles were 0.06-0.07
and 0.36-0.37) [18,19].
In this study, our data demonstrate that the risk of
severe acute dermatitis up to grade 3 after radiotherapy
could be increased by 2.65-fold in patients carrying with
the XRCC1 399Arg/Gln genotype. There was no associ-
ation between the XRCC1 194Arg/Trp genotype and skin
reaction.
Although our observations have not been reported
previously, they are strongly supported by information
from relevant publications. The XRCC1 399Arg/Gln ge-
notype has been reported to be associated with radiation
sensitivity [8], mutagen sensitivity [9] and risk for lung
cancer [20]. Furthermore, in a genotype-phenotype
investigation, Au et al. [21] reported that the XRCC1
399Arg/Gln genotype was associated with reduced repair
capacity for radiation-induced DNA damage but with
normal repair of UV-light induced damage compared
with the wild-type genotype. On the other hand, the
XRCC1 194Arg/Trp genotype had repair activities similar
to that of the wild-type. Therefore, our observations are
likely to be real. Regarding the effects of the polymorph-
ism of XRCC1 on oral mucositis, there was no report
about the association between XRCC1 (194Arg/Trp and
399Arg/Gln) genotypes and oral mucositis in the litera-
ture. However, polymorphisms in XRCC3 were not asso-
ciated with risk of oral mucositis [6].
Our results also showed that patients carrying with the
XRCC1 (399Arg/Gln) genotype trended to have higher
incidence of grade 3 oral mucositis. The odds ratio was
2.11 (p = 0.065, χ2 = 3.411). We did not find the rela-
tionship between polymorphism of XRCC1 (194Arg/Trp)
and oral mucositis. This further demonstrated that the
XRCC1 (399Arg/Gln) genotypes was linked to increased
susceptibility of normal tissues to irradiation.
In the published literature, three reports were found
which demonstrated the specific contribution of XRCC1
399Gln towards the expression of radiosensitivity. The
first two reports by Hu et al. [8,22] showed that exten-
sive radiation-induced cell cycle delay was associated
with the variant gene in cells from normal individuals
and from breast cancer patients. The third report [21] is
from our co-author who demonstrated that the variant
gene showed DNA repair of radiation-induced but not
UV-induced DNA damage. However, whether the repair
was normal or not was not investigated. Therefore, these
three reports, in combination, revealed that the variant
gene may have abnormal DNA repair function (e.g.
mistakes in repair) which can cause radiosensitivity. In
this context, the three reports validate our observation
of radiation sensitivity towards dermatitis and mucositis
in our patients.
Conclusions
In summary, our study illustrates, for the first time, that
patients with the XRCC1 (399Arg/Gln) genotype were
more likely to experience severe acute radiation-induced
dermatitis and oral mucositis after radiation therapy. With
further validation, the genotype information may be useful
in determining personalized radiotherapy strategy.
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